Index
Grant: Stanford University — Universal Flu Drug Research (Jeffrey Glenn) (Coefficient Giving → Stanford University)
Verdictconfirmed95%
1 check · 4/9/2026Deterministic match: grantee, amount, date matched in source snapshot (2714 rows)
Our claim
entire record- Grantee
- Stanford University
- Name
- Stanford University — Universal Flu Drug Research (Jeffrey Glenn)
- Amount
- $415,000
- Currency
- USD
- Date
- July 2020
- Notes
[Scientific Research] Grant investigators: Heather Youngs and Chris Somerville This page was reviewed but not written by the grant investigators. Stanford University staff also reviewed this page prior to publication. Open Philanthropy recommended a grant of $415,000 to Stanf… expand
[Scientific Research] Grant investigators: Heather Youngs and Chris Somerville This page was reviewed but not written by the grant investigators. Stanford University staff also reviewed this page prior to publication. Open Philanthropy recommended a grant of $415,000 to Stanford University to support work led by Professor Jeffrey Glenn to test the efficacy of a universal antiviral drug candidate against all influenza strains. An effective pan-influenza antiviral drug could avert hundreds of thousands of deaths annually and minimize the spread of highly infectious and lethal strains of the virus. Professor Glenn intends to use this funding to conduct protective assays in ferrets, a transmission study, and a pharmacokinetics and distribution analysis. This follows our June 2020 support and falls within our work on scientific research, specifically within our interest in science supporting biosecurity and pandemic preparedness.
Source evidence
1 src · 1 checkconfirmed95%deterministic-row-match · 4/9/2026
- Name
- Stanford University — Universal Flu Drug Research (Jeffrey Glenn)
- Grantee
- Stanford University
- Focus Area
- Scientific Research
- Amount
- $415,000.00
- Date
- July 2020
- Description
- G
NoteDeterministic match: grantee, amount, date matched in source snapshot (2714 rows)
Case № pP6Ep0gDDoFiled 4/9/2026Confidence 95%